2 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 2 of 2 clinical reviews.
Deep-dive into post-trial follow-up from DEVOTE: durability of degludec's CV safety signal, long-term hypoglycemia patterns, and what emerged after the key 2017 NEJM publication.
A deep dive into the DEVOTE trial's primary and secondary endpoint results, effect sizes, confidence intervals, subgroup analyses, and hypoglycemia outcomes for insulin degludec vs glargine U100 in type 2 diabetes.
LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.